China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC – Get Free Report) was the target of a large growth in short interest during the month of June. As of June 15th, there was short interest totaling 71,896 shares, a growth of 1,295.8% from the May 31st total of 5,151 shares. Currently, 0.2% of the shares of the company are short sold. Based on an average trading volume of 220,625 shares, the days-to-cover ratio is presently 0.3 days.
Hedge Funds Weigh In On China SXT Pharmaceuticals
A number of hedge funds have recently modified their holdings of SXTC. XTX Topco Ltd purchased a new stake in shares of China SXT Pharmaceuticals in the fourth quarter worth $36,000. Citadel Advisors LLC purchased a new position in shares of China SXT Pharmaceuticals during the 3rd quarter valued at $78,000. Finally, Virtu Financial LLC lifted its stake in shares of China SXT Pharmaceuticals by 107.5% during the 3rd quarter. Virtu Financial LLC now owns 28,983 shares of the company’s stock valued at $46,000 after buying an additional 15,013 shares in the last quarter. 5.02% of the stock is currently owned by institutional investors.
China SXT Pharmaceuticals Trading Up 3.0%
Shares of NASDAQ:SXTC opened at $2.42 on Friday. The stock has a 50 day moving average of $1.90 and a 200 day moving average of $41.70. China SXT Pharmaceuticals has a 12-month low of $1.25 and a 12-month high of $1,046.98.
Analysts Set New Price Targets
Get Our Latest Stock Analysis on SXTC
China SXT Pharmaceuticals Company Profile
China SXT Pharmaceuticals Inc (NASDAQ: SXTC) is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of peptide-based therapeutics. The company’s pipeline centers on novel treatments targeting oncology, endocrine and metabolic disorders. By leveraging proprietary peptide synthesis and formulation technologies, China SXT aims to advance next-generation biologics that address unmet medical needs in both domestic and international markets.
The company’s core product candidates include long-acting peptide hormones and peptide-drug conjugates designed to improve patient compliance and therapeutic efficacy.
Featured Articles
- Five stocks we like better than China SXT Pharmaceuticals
- 3 Overlooked Tech ETFs That Are Quietly Killing It This Year
- 3 ETFs Pairing Market-Beating Returns With High Dividend Yields
- MarketBeat Week in Review – 06/22 – 06/26
- Rocket Lab’s NASA Win Tests Key Support After Sharp Pullback
Receive News & Ratings for China SXT Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China SXT Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
